|
CLINICAL TAKEAWAY
| Domain |
Key Finding |
Evidence Level |
| CV Mortality |
~14% all-cause mortality reduction; ~21% relative reduction in major vascular events per 1 mmol/L LDL lowered |
Strong (RCT meta-analysis) |
| Side Effects |
90% of symptom burden is nocebo; no difference between statin and placebo in blinded crossover (SAMSON) |
Strong (NEJM, n-of-1 RCT) |
| Cancer Risk |
RCTs show no effect on cancer incidence; observational data suggests site-specific reductions (liver, colorectal). Signal is hypothesis-generating, not confirmed. |
Weak–Moderate (conflicting) |
| Dementia / AD |
New RWD analysis (Novak 2026, n=838K PSM): RR=0.69 for AD. Cochrane RCTs (n=26K) remain negative for late-life initiation. Signal is accumulating — causality unproven. |
Conflicted — RWD signal strengthening; RCT data negative for late life |
| Cost |
All major statins are generic; widely available for <$10/month, often covered with $0 copay |
Established fact |
|
|
Every morning I open the same orange bottle, tap out a small white pill, and swallow it without ceremony. I'm 36. I have no symptoms. I haven't had a heart attack. My cardiologist hasn't referred me anywhere. I started this four years ago — not out of fear, but out of an honest accounting of the evidence.
